Clinical Trial

A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The study is being conducted to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in patients with recurrent/metastatic cervical cancer or ovarian cancer failed or intolerance to standard first-line therapy.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-01-09; most recent amendment 2026-04-17.
Status change: Not Yet Recruiting → Recruiting 2025-02-24
Trial Details
NCT Number NCT06769152
Lead Sponsor Shanghai Henlius Biotech
Conditions Cervical Cancer, Ovarian Cancer
Enrollment 190 participants
Start Date 2025-02-20
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-06-05 (estimated)
Updated on ClinicalTrials.gov 2026-04-22